Using MRI scans to predict early response to chemotherapy in bladder cancer
Studies whether special MRI scans can predict early response to chemotherapy before bladder surgery.
Plain-language title generated from the registry record
Registry title: Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI
Key facts
- Where
- Asyut, EgyptSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with muscle-invasive bladder cancer who plan to get cisplatin-based chemotherapy before bladder removal surgery. They will have three MRI scans.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Urothelial bladder cancer, stage cT2-T4, with no distant metastases at diagnosis
- Earlier treatment
- Must not have had pelvic radiotherapy or earlier open or laparoscopic pelvic surgery. Must be planned for cisplatin-based chemotherapy followed by radical cystectomy.
Main reasons for not taking part
- Pelvic radiotherapy in the past
- Severe renal impairment
- Earlier open or laparoscopic pelvic surgery
- Distant metastases at diagnosis
- Contraindication to MRI or to cisplatin
Read by machine on 12 November 2026.
Where in Egypt
- Amr E. DarwishAsyut, EgyptContact: Urology Department, Faculty of Medicine, Assiut University Dr, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assiut University
- Trial code
- NCT07202845
- Record updated
- 2 October 2025
- Original description
Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable muscle-invasive bladder cancer (MIBC). However, non-response to NAC can lead to delayed surgery and unnecessary toxicity. Magnetic resonance imaging (MRI), particularly multiparametric MRI (mpMRI) with dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI), offers functional and quantitative biomarkers that may predict NAC response early in treatment.Read full original descriptionShow less
Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI
Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable muscle-invasive bladder cancer (MIBC). However, non-response to NAC can lead to delayed surgery and unnecessary toxicity. Magnetic resonance imaging (MRI), particularly multiparametric MRI (mpMRI) with dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI), offers functional and quantitative biomarkers that may predict NAC response early in treatment.
Inclusion: Patients diagnosed with cT2-T4 urothelial carcinoma of the urinary bladder, according to the TNM classification (8), who give informed, written consent on participation in the study and approve all its requirements; Planned to receive cisplatin-based NAC followed by radical cystectomy; Willing to undergo three mpMRI scans (baseline, 24h post-initial cisplatin, and post-NAC).
Exclusion: Patients who have received pelvic radiotherapy; Previous open or laparoscopic pelvic surgery; Severe renal impairment; Presence of distant metastases at diagnosis; Patients with contraindications to MRI; Ineligibility to cisplatin.